Next 10 |
home / stock / sabs / sabs articles
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biop...
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage bioph...
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage bioph...
Shares of Applied Therapeutics, Inc. (NASDAQ: APLT) shares fell sharply during Friday’s session after the company released topline results ...
With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street ...
The Dow Jones closed higher by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern ar...
SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MA...
SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel ...
Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditions Participat...
News, Short Squeeze, Breakout and More Instantly...
SAB Biotherapeutics Inc. Company Name:
SABS Stock Symbol:
NASDAQ Market:
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIg...
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biop...
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIg...